According to IQVIA, the research will ascertain whether clinical benefits observed for treatments in clinical trials match with the benefits of the therapies in real-world settings.
RWE uses dynamic data and other assets like EMR, hospital, pharmacy, and claims sources. The research also uses genomics, mobile health, and patient-reported outcomes.
This project is part of the Friends of Cancer Research initiative that works towards demonstrating the application of RWE in cancer research.
A recent study as part of the project saw six US research centres follow protocol to evaluate real-world endpoints in cancer patients. This included time to next treatment, overall survival, time to treatment discontinuation, progression-free survival and time to progression.
The results were published in the JCO Clinical Cancer Informatics and were titled ‘An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer’.
IQVIA Real-World Solutions chief scientific officer Nancy Dreyer said: “While randomised clinical trials are the gold standard to evaluate whether a medical treatment can work, they don’t determine if treatment works for diverse patients outside the clinical setting and within real-world situations.
“IQVIA is excited to be part of this initiative. This important study demonstrates the value of real-world evidence to measure and quantify the comparative benefits and risks of various medical products.”
Non-identified patient data from administrative claims and electronic health records were used to evaluate real-world endpoints and the researchers found that the results were consistent with results obtained from randomised clinical trials.